Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H11FN2O2 |
| Molecular Weight | 257.2503 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC1=NC([18F])=C(C=C1)C2=CC3=C(O2)C=CC(O)=C3
InChI
InChIKey=MYNQXTDIPMCJCR-HUYCHCPVSA-N
InChI=1S/C14H11FN2O2/c1-16-13-5-3-10(14(15)17-13)12-7-8-6-9(18)2-4-11(8)19-12/h2-7,18H,1H3,(H,16,17)/i15-1
| Molecular Formula | C14H11FN2O2 |
| Molecular Weight | 257.2503 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Flutafuranol F-18 (also known as NAV4694), a fluorine-18 labeled positron emission tomography (PET) imaging agent that was developed for diagnostic use. Flutafuranol F-18 binds to beta-amyloid deposits in the brain that could then be imaged in PET scans. It is known that amyloid plaque pathology is a required feature of Alzheimer’s disease (AD) and the presence of amyloid pathology is a supportive feature for the diagnosis of probable AD. Patients who are negative for amyloid pathology do not have AD. Thus, flutafuranol F-18 was studied in phase III clinical trial as an aid in the imaging for patients with Alzheimer’s disease and in phase II clinical trial for patients with mild cognitive impairment.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL. | 2018-12 |
|
| The Binding of BF-227-Like Benzoxazoles to Human α-Synuclein and Amyloid β Peptide Fibrils. | 2018-09-15 |
|
| Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale. | 2016-08 |
|
| Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia. | 2013-06 |
|
| [The effect of propranolol and flusoxolol on the lysosomal enzyme activity of the rat ventricular myocardium]. | 1992-09-01 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01886820
Intravenous [18F]NAV4694 radioactive dose 8.1 mCi(300 MBq) given once
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:51:33 GMT 2025
by
admin
on
Mon Mar 31 20:51:33 GMT 2025
|
| Record UNII |
785H5FQN20
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
785H5FQN20
Created by
admin on Mon Mar 31 20:51:33 GMT 2025 , Edited by admin on Mon Mar 31 20:51:33 GMT 2025
|
PRIMARY | |||
|
C171890
Created by
admin on Mon Mar 31 20:51:33 GMT 2025 , Edited by admin on Mon Mar 31 20:51:33 GMT 2025
|
PRIMARY | |||
|
10015
Created by
admin on Mon Mar 31 20:51:33 GMT 2025 , Edited by admin on Mon Mar 31 20:51:33 GMT 2025
|
PRIMARY | |||
|
CHEMBL2048308
Created by
admin on Mon Mar 31 20:51:33 GMT 2025 , Edited by admin on Mon Mar 31 20:51:33 GMT 2025
|
PRIMARY | |||
|
1211333-21-9
Created by
admin on Mon Mar 31 20:51:33 GMT 2025 , Edited by admin on Mon Mar 31 20:51:33 GMT 2025
|
PRIMARY | |||
|
AB-134
Created by
admin on Mon Mar 31 20:51:33 GMT 2025 , Edited by admin on Mon Mar 31 20:51:33 GMT 2025
|
PRIMARY | |||
|
44815683
Created by
admin on Mon Mar 31 20:51:33 GMT 2025 , Edited by admin on Mon Mar 31 20:51:33 GMT 2025
|
PRIMARY | |||
|
100000175357
Created by
admin on Mon Mar 31 20:51:33 GMT 2025 , Edited by admin on Mon Mar 31 20:51:33 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->RADIOLIGAND |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |